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The generation of antitumour immunity depends on the nature of dendritic cell (DC)–tumour interactions. These have been studied
mostly by using in vitro-derived DC which may not reflect the natural biology of DC in vivo. In breast cancer, only one report has
compared blood DC at different stages and no longitudinal evaluation has been performed. Here we conducted three cross-sectional
and one one-year longitudinal assessments of blood DC in patients with early (stage I/II, n¼137) and advanced (stage IV, n¼36)
disease compared to healthy controls (n¼66). Patients with advanced disease exhibit markedly reduced blood DC counts at
diagnosis. Patients with early disease show minimally reduced counts at diagnosis but a prolonged period (1 year) of marked DC
suppression after tumour resection. While differing in frequency, DC from both patients with early and advanced disease exhibit
reduced expression of CD86 and HLA-DR and decreased immunostimulatory capacities. Finally, by comparing a range of clinically
available maturation stimuli, we demonstrate that conditioning with soluble CD40L induces the highest level of maturation and
improved T-cell priming. We conclude that although circulating DC are compromised by loco-regional and systemic breast cancer,
they respond vigorously to ex vivo conditioning, thus enhancing their immunostimulatory capacity and potential for immunotherapy.
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Dendritic cells (DC) are antigen-presenting cells (APC) that play a
central role in initiating and directing cellular and humoral
responses including antitumour immunity (Banchereau et al,
2000). These APC play a clinically important role in the defence
against cancer as increased numbers of tumour-infiltrating DC
correlate with better clinical prognosis (Zeid and Muller, 1993;
Lespagnard et al, 1999). Tumours, however, employ numerous
mechanisms to evade immune elimination including DC suppres-
sion (Pinzon-Charry et al, 2005b). Assessing the in vivo effects of
tumours on DC is difficult and limited by their paucity in
peripheral blood (Ho et al, 2002) and tissues. Hence, DC–tumour
interactions have been addressed mostly by using DC derived in
vitro from CD34
þ or monocyte precursors following culture with
cytokines (Menetrier-Caux et al, 1998; Sombroek et al, 2002;
Peguet-Navarro et al, 2003). Nonetheless, cytokine-driven activity
may not reflect the functional status of DC circulating in vivo and
thus detailed evaluation of blood DC at different stages of tumour
progression is necessary.
Circulating DC play a critical role in shaping antitumour
responses by continually replenishing the pool of tissue-residing
DC (Banchereau et al, 2000). These cells can be identified by their
high levels of HLA-DR and lack of specific lineage markers (CD3,
CD14, CD19, CD20, CD56 and CD34) expressed on other
leucocytes (Thomas et al, 1993b; Savary et al, 1998). Few reports
have assessed the effects of tumours on blood DC ex vivo
(Gabrilovich et al, 1997; Hoffmann et al, 2002; Ratta et al, 2002;
Della Bella et al, 2003) possibly due to their scarcity and
heterogeneous nature. In the case of breast cancer, circulating
DC have been shown to be numerically reduced (Della Bella et al,
2003), exhibit increased rates of apoptosis (Pinzon-Charry et al,
2005c), and reduced capacity to stimulate T cells (Gabrilovich
et al, 1997; Satthaporn et al, 2004). The DC compartment has also
been shown to exhibit increased number of immature cells with
impaired antigen-presenting capacity (Pinzon-Charry et al,
2005a,d). To date, however, only one – rather small – study has
compared blood DC at different stages of disease (Gabrilovich
et al, 1997) and no longitudinal studies have been reported.
The aim of this study was to monitor the blood DC
compartment in patients with early- and late-stage breast cancer
to ascertain any correlation between DC abnormalities and burden
of disease, and identify factors suitable for clinical implementation
to improve DC function. Cross-sectional and longitudinal assess-
ments were performed in 173 patients with locally limited or
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smetastatic disease, and results compared with 66 healthy controls.
Given the low frequency of blood DC and restricted blood volumes
that could be taken from patients, sub-cohorts were used for the
various analyses aiming to (i) estimate blood DC numbers and
their correlation with other blood counts, (ii) assess the
immunostimulatory profile of blood DC and (iii) identify factors
suitable for clinical implementation to functionally improve
blood DC.
MATERIALS AND METHODS
Study subjects and design
A total of 173 female patients, 40–83 years of age, with
histologically confirmed breast adenocarcinoma were enrolled in
the study. Of these, 137 patients presented with early disease,
either local stage I (T1N0M0; n¼78) or nodal stage II (T2N1M0;
n¼59) and 36 patients presented with advanced metastatic stage
IV (TNM1). In addition, 66 age-matched, female, healthy donors
volunteered for the study and served as controls. All 137 patients
with early-stage disease were newly diagnosed. Of the 36 patients
with advanced disease, six were newly diagnosed and 30 presented
with recurrence after a disease-free interval and no prior therapy
for at least 7 months (range of 7–127 months, mean of 60 months).
Staging was performed in accordance with the International Union
Against Cancer (UICC) TNM classification (Sobin and Wittekind,
2002). Blood samples were collected prior to therapy except for the
longitudinal study where in addition to the sample collected 2
weeks prior to surgery, follow-up samples were collected at 6, 24
and 48 weeks post-surgery. The 6 and 24 weeks samples were
collected before and immediately after completion of the radio/
chemotherapy regimens, respectively. For the longitudinal follow-
up, 40 patients (all receiving hormone therapy) were divided into
those receiving hormone therapy and either radiotherapy (n¼9),
chemotherapy (n¼11) or combined therapy (n¼20). Three stage
I patients (n¼3) not receiving hormone therapy (yet administered
radiotherapy) were also included for comparison. The Australian
Red Cross Blood Service provided buffy coats. Written informed
consent was obtained from all patients and the study was approved
by the Human Ethics Committees of clinical (Mater Health
Services and Wesley Medical Centre) and research (Queensland
Institute of Medical Research) institutions.
Monoclonal antibodies, reagents and media
The following monoclonal antibodies were used: CD3, CD4, CD19,
CD20, CD56, CD34, HLA-DR, CD40, CD80, CD83, CD86, CD11c,
CD123 and IgG1, IgG2a and IgG2b isotype controls from BD
Pharmingen (BD Biosciences, San Jose, CA, USA); HLA-DR, CD19
and IgG1 isotype control from Beckman Coulter (Fullerton, CA,
USA) and IL-12 from Caltag Laboratories (Burlingame, CA, USA).
All antibodies were used as fluorescein isothiocyanate (FITC),
phycoerythrin (PE), biotin, allophycocyanin (APC) or PE-Cy5
conjugates. Complete media included RPMI 1640 supplemented
with 10% foetal calf serum (FCS), penicillin (100Uml
 1),
streptomycin (100mgml
 1), L-glutamine (2mM), HEPES (25mM)
and nonessential amino acids, all purchased from Gibco Life
Technologies (Gaithesburg, MD, USA). The combination of pro-
inflammatory cytokines consisted of IL-1b (10ngml
 1), IL-6
(10ngml
 1) and TNF-a (10ngml
 1) obtained from R&D systems
(Minneapolis, MN, USA), plus prostaglandin E2 (PGE2,1mgml
 1)
from Sigma (St Louis, MI, USA). Double-stranded RNA (polyI:C;
50mgml
 1) and lipopolysaccharide (LPS; 50ngml
 1) were pur-
chased from Sigma. The CpG oligodeoxynucleotide 2216 (CpG;
3mgml
 1) was acquired from Geneworks (Melbourne, Victoria,
Australia). The soluble human recombinant trimetric CD40 ligand
(CD40L; 2mgml
 1) was kindly provided by Amgen (Seattle, WA,
USA). Tetanus toxoid (TT) obtained from CSL (Melbourne,
Victoria, Australia) was conjugated to FITC (FITC-TT) in-house
and dialysed in phosphate-buffered saline (PBS) for 48h before
use. Dialysis membranes (Polylabo, Strassbourg, France) with an
MW cutoff of under 10000–14000 were used. FITC-dextran was
obtained from Sigma and sheep red blood cells from Equicell
(Melbourne, Victoria, Australia).
Flow cytometry
Following venous blood collection in heparinised tubes, peripheral
blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque
centrifugation. Cells were stained with the lineage (Lin) mixture
(CD3, CD14, CD19, CD20, CD56 and CD34, all FITC) and HLA-DR
(PE-Cy5). Three or four colour flow cytometry (FACS) was used to
evaluate DC numbers, phenotype, antigen uptake and cytokine
secretion. Blood DC were defined as lineage (Lin) negative and
HLA-DR positive events (Lin
 HLA-DR
þ cells). Dendritic-cell
subsets were identified using CD11c (APC) and CD123 (PE).
Antigen uptake was assessed after cells were incubated (10
7
cellsml
 1; 60min) with FITC-TT (0.5mgml
 1) or FITC-dextran
(1mgml
 1) at either 41Co r3 7 1C. Antigen capture was calculated
as the difference in mean fluorescence intensity (DMFI) between
the test (371C) and the control (41C). Phenotypic maturation was
assessed after culture (10
7 cellsml
 1) for 18–36h in the presence
of a combination of inflammatory cytokines (IL-1b, IL-6, TNF-a
and PGE2; CC), poly I:C (PIC) or CD40L (in addition to IFN-g and
IL-1b). Where indicated, culture supernatants were collected and
assayed using an IL-12 p70 ELISA kit (Mabtech AB, Nacka Strand,
Sweden). Intracellular cytokine staining was performed by
stimulating cells as above in the presence of brefeldin-A
(10mgml
 1, Sigma). Cells were labelled, fixed with 1% parafor-
maldehyde and stained with anti-IL-12-PE in 0.2% saponin/PBS at
41C overnight. In all experiments, 5 10 10
5 events were collected
within the mononuclear gate. Absolute DC counts (10
6l
 1) were
calculated from the number of PBMC per litre of blood (as
determined by the automated cell counter) multiplied by the
percentage of DC (mean of triplicates) determined by FACS
analysis. Routine differential blood count measurements (10
9l
 1)
were performed using automated cell counters (Advia 120,
Haematology System or Technicon H.3 RTX Bayer, Tarrytown,
NY, USA). All data were acquired on an FACS calibur flow
cytometer and analysed using CellQuest 3.1 (BD Biosciences) or
Summit (Cytomation, Fort Collins, CO, USA) software.
Cell purification and culture
Following isolation of PBMC, cells were stained with lineage
mixture (FITC), HLA-DR (PE) and CD11c and CD123 (APC). As a
viability indicator, 7AAD (Sigma) was included. Viable DC
(Lin
 HLA-DR
þ CD11c
þ CD123
þ cells) were sorted (99% purity)
using MoFlo Sorter (Cytomation) and resuspended in complete
medium. Allogeneic T cells were purified from buffy coats by
rosetting PBMC with neuraminidase-treated sheep red blood cells
(490% CD3
þ T cells). Alternatively, CD4
þ T cells were purified
by positive immunoselection with anti-CD4 microbeads (490%
CD4
þ T cells; Miltenyi Biotec, GmbH, Bergisch Gladbach,
Germany). Varying numbers of DC from breast cancer patients
were cultured with allogeneic T cells purified from healthy donors
and incubated for 5 days in complete medium. At 16h prior to
harvesting, 1mCiwell
 1 of
3H-thymidine was added to each well
and thymidine incorporation was measured in a b-scintillation
counter (MicroBeta Trilux Scintillation Counter, Wallac, Turku,
Finland). For measurements of IFN-g secretion, after 5 days in
culture, supernatants were collected, pooled and assayed using an
ELISA kit (Mabtech).
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sStatistical analysis
Statistical evaluation of the data was performed using GraphPad
Prism (GraphPad Software, San Diego, CA, USA). One-way
analysis of variance (ANOVA) followed by Bonferroni’s comparison
test were used to analyse significance between different sub-
cohorts of patients and controls, and between the pre-operative
and subsequent time points in the longitudinal follow-up study.
Results were considered to be statistically significant when
Po0.05. For values of proliferation presented in Figure 3E, paired
T tests were used.
RESULTS
Dendritic cell counts are reduced in advanced disease
Blood DC can be identified by flow cytometry as lineage negative
(Lin
 ), HLA-DR positive (HLA-DR
þ) cells (Thomas et al, 1993a;
Figure 1A). In order to determine whether the burden of disease
could have an impact on blood DC numbers in breast cancer, we
estimated Lin-HLA-DR
þ counts prior to therapy in a cohort of 49
patients grouped according to stage of disease into local (stage I;
n¼23), nodal (stage II, n¼11) or metastatic (stage IV, n¼15)
disease, and compared these to controls (n¼12). To limit a role
for previous diagnosis/treatment in counts, analyses of early-stage
disease were limited to newly diagnosed patients, and advanced
disease patients were stratified into those previously diagnosed
(pIV, n¼9), thus presenting with recurrence after a disease-free
interval (mean of 60 months), and those newly diagnosed (nIV,
n¼6) thus presenting for the first time. Although blood DC counts
were only discretely reduced (not significant) in patients with early
disease (stage I and II) compared to controls (Figure 1B), they were
markedly diminished in all patients with advanced disease
irrespective of their status (previously vs newly diagnosed),
suggesting a direct effect of tumour progression on DC. The
reduction in DC counts was, however, not generalised to all other
mononuclear cells as lymphocytes, but not monocytes, decreased
in advanced disease (Figure 1C–D). Given that the blood DC
compartment has been reported to include different DC lineages
including myeloid (CD11c
þDC) and plasmacytoid (CD123
þDC)
DC (Robinson et al, 1999), we assessed the DC subset distribution
in these patients (Figure 1E–H). There was a trend of declining
CD11c
þDC and CD123
þDC counts with disease progression
(Figure 1F–G). While CD11c
þDC and CD123
þDC numbers were
comparable in controls and patients with local disease, they
were significantly reduced in advanced disease (Figure 1F–H). We
also confirmed the concurrent accumulation of immature
CD11c
 CD123
  cells in peripheral blood of patients with
advancing disease (Figure 1H), as previously described (Pinzon-
Charry et al, 2005a).
Dendritic cell counts are reduced in early disease upon
follow-up
Given that DC counts in patients with early disease were only
modestly reduced at first assessment (Figure 1), we set out to
carefully monitor DC at various times over a 1-year interval in a
comparable cohort of patients. Here, 40 patients with early disease
(stage I, n¼26 and stage II, n¼14) undergoing surgery were
assessed 2 weeks pre-operatively, and at 6, 24 and 48 weeks after
surgery. As shown in Figure 2A, we found a progressive decline in
DC counts starting as early as 6 weeks post surgery (prior to
initiation of adjuvant therapy) reaching a nadir at 24 weeks
(immediately after completion of adjuvant chemo- and radio-
therapy) and persisting until the 48-weeks assessment. Notably,
DC counts did not return to pre-operative levels in any patient
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Figure 1 Blood DC counts at diagnosis. (A) A representative dot plot of PBMC from a patient with breast cancer (stage II) where blood DC are
identified in the elliptical gate as lineage-negative, HLA-DR positive cells. (B–D) Mononuclear cell population counts including (B) DC, (C) lymphocytes and
(D) monocytes were assessed in a cohort of 49 patients with breast cancer (stage I, n¼23; stage II, n¼11 and stage IV, n¼15) and compared with age-
matched female controls (n¼12). Patients with advanced disease were divided into patients previously (pIV, n¼9) or newly diagnosed (nIV, n¼6). (E)
Blood DC (gated as in A) in patients with breast cancer can be further analysed for DC subsets within a CD11c/CD123 bivariate plot. A representative dot
plot of a patient with stage II disease is shown. (F–H) Blood DC subsets were analysed in 43 patients to determine absolute counts of (F) CD11c
þDC, (G)
CD123
þDC and (H) CD11c
 CD123
  immature cells. Absolute DC and DC subset counts are expressed as 10
6l
 1 and all other counts are expressed as
10
9l
 1. Shaded areas indicate normal reference ranges. Box plots with means, standard deviations and ranges are shown. Significant differences compared to
controls are indicated as *Po0.05 and **Po0.01. All samples were analysed prior to therapy.
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s(data not shown). As shown in Figure 2B, lymphocyte counts
showed comparable changes to DC, decreasing significantly at 6
weeks and remaining suppressed until the 48-weeks assessment.
Monocyte, neutrophil and platelet counts, however, revealed
minimal changes over the matched interval (Figure 2C–E). In
our previous study of healthy individuals undergoing surgery, DC
counts returned to pre-operative levels within 1 week (Ho et al,
2001). Hence, we hypothesised that adjuvant therapy could be
playing a role in the impaired DC count recovery. Because the 40
patients in our follow-up study received hormone therapy
(Tamoxifen), the effect of other treatment modalities was evaluated
by grouping subjects according to whether they also received
chemo-, radio- or combined therapy (chemo and radiotherapy).
Notwithstanding their limited number, DC counts of three patients
not receiving hormone therapy (yet receiving radiotherapy) were
included for comparison (labelled as radio without Tamoxifen in
Figure 2F–J). In all patients, DC counts were estimated after
completion of their radio/chemotherapeutic regimen (24 weeks
after surgery) and compared to the pre-surgery (Pre-Sx, -2 weeks)
and pre-adjuvant therapy (Pre-AT, 6 weeks) assessments. Patients
on hormone therapy were on Tamoxifen at the time of evaluation.
Despite the different course of therapy (local, systemic or
combined), DC numbers fell significantly in all groups compared
to the pre-surgery assessment (Figure 2F). Lymphocyte counts
were also markedly reduced in all groups. Patients not on hormone
therapy (but receiving radiotherapy) demonstrated moderate (not
significant) reduction in DC and lymphocyte counts. Patients
receiving local radiotherapy (with or without hormone therapy)
exhibited moderately (not significant) higher counts than patients
receiving chemo- or combined therapy (Figure 2G). Monocyte,
neutrophil and platelet counts showed little or no alteration in
either group during corresponding assessments (Figure 2H–J).
Dendritic cells exhibit impaired immunostimulatory
phenotype
Next, we set out to determine if numerical alterations of blood DC
were associated with phenotypic or functional abnormalities in
early and/or advanced disease. Because expression of MHC II and
costimulatory molecules on the surface of DC from cancer patients
has been correlated to their immunostimulatory capacity
(Gabrilovich et al, 1997), we evaluated the expression of HLA-
DR and CD86 in 40 patients with early and advanced disease (stage
I, n¼19; stage II, n¼12 and stage IV, n¼9) compared to controls
(n¼14). These patients exhibited DC counts comparable to those
observed in the previous cohort (mean±s.e.m.; controls:
18.7±2.7; stage I: 13.3±1.1; stage II: 13.6±1.93 and stage IV:
8.9±1.8), confirming the significant reduction in DC counts in
advanced disease. In this group, DC from patients with early
disease showed a discrete (not significant) reduction in the
expression of CD86 and HLA-DR compared to controls, while
DC from patients with advanced disease showed significantly lower
levels of these molecules on their surface (Figure 3A–B). The
proportion of DC expressing CD86 was also significantly (Po0.05)
reduced in advanced disease (data not shown). To further assess
DC in these patients, we tested their capacity to capture antigens
and stimulate proliferation and cytokine secretion in allogeneic T
cells. We found that DC from controls (n¼4) had a significantly
higher capacity to take up soluble (FITC-TT) and particulate
(FITC-Dextran) antigens compared to DC from both, early (stage
II, n¼4) and advanced (stage IV, n¼4) disease (Figures 3C–D).
Moreover, DC from patients with early (stage II, n¼6) and
advanced (stage IV, n¼3) disease induced significantly reduced
proliferation of allogeneic T cells (Figure 3E–F) and were poor
stimulators of IFN-g secretion (Figure 3G) compared to DC from
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Figure 2 Blood DC counts follow-up. In a cohort of 40 patients with early-stage disease (stage I, n¼26 and stage II, n¼14), absolute counts of (A) DC,
(B) lymphocytes, (C) monocytes, (D) neutrophils and (E) platelets were estimated at 6, 24 and 48 weeks post-surgery and compared to the pre-operative
assessment ( 2). (F–J) To assess the effect of the type of adjuvant therapy, the 40 patients were divided into those receiving hormone therapy (Tamoxifen,
Tamox) and either radiotherapy (n¼9; Radio), chemotherapy (n¼11, Chemo) or combined therapy (n¼20; Comb.). Three patients (n¼3) not receiving
hormone therapy (yet administered radiotherapy) were also included for comparison. Subsequently, (F) blood DC, (G) lymphocyte, (H) monocyte, (I)
neutrophil and (J) platelet counts were estimated for the 24-week point (immediately after completion of radio/chemotherapy) and compared to the pre-
surgery (Pre-SX,  2 weeks) and pre-adjuvant therapy (Pre-AT, 6 weeks) assessments. Note that Pre-AT corresponds to post-surgical evaluation. Absolute
DC counts are expressed as 10
6l
 1 and all other counts expressed as 10
9l
 1. Shaded areas indicate normal reference ranges. Box plots with means,
standard deviations and ranges are shown. Significant differences compared to pre-operative are shown as *Po0.05, **Po0.01 and ***Po0.001.
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removal on the functional phenotype of blood DC, we assessed DC
counts and activation status in six patients with stage II disease
before (at diagnosis) and 24 weeks after completion of therapy (24
weeks after completion of radio/chemotherapy and 48 weeks after
surgery). While DC and lymphocyte numbers were markedly
decreased, all other blood counts (monocytes, neutrophils and
platelets) showed minimal or no alteration, in accordance with our
longitudinal study. No significant changes in DC phenotype were
observed after completion of therapy as assessed by CD40 and
CD86 expression (Supplementary Figure 1).
Dendritic cells respond vigorously to in vitro conditioning
with CD40L
Aiming to identify factors that could improve the function of DC
from breast cancer patients in a clinical setting, we assessed the
functional maturation induced by three different types of stimuli
currently under investigation for immunotherapy. First, we tested
(i) a combination of inflammatory cytokines (IL-1b, IL-6, TNF-a
and PGE2; CC; Jonuleit et al, 1997), (ii) synthetic double-stranded
RNA (polyI:C; PIC; Cella et al, 1999) and (iii) CD40 ligand (CD40L;
Terheyden et al, 2000) in DC from patients with early-stage disease
(stage II, n¼8). While all types of maturation stimuli induced
significant increases in the expression of CD86 and HLA-DR,
CD40L was the most potent stimulus of phenotypic maturation for
blood DC in these patients (Figure 4A–B). In contrast to CC and
PIC, CD40L induced robust secretion of IL-12 in DC from patients,
although not reaching control levels (Figure 4C–D). While DC
conditioned with CC or PIC exhibited enhanced stimulatory
abilities (T-cell proliferation and IFN-g secretion) compared to
unconditioned DC, CD40L remained the most potent stimulus to
improve the immunostimulatory capacity of DC from patients
(Figure 4E–F). Interestingly, addition of PIC to CD40L did not
further improve the enhancement of DC induced by CD40L alone
in either patients or controls (Figure 4A–F). To assess the
functional maturation of DC from advanced disease patients (stage
IV, n¼5), we also tested their response to stimulation with CC and
various ligands for toll-like receptors (TLR) including TLR4
(lipopolysaccharide, LPS), TLR3 (PIC) and TLR9 (bacterial
oligodeoxynucleotide CpG, CpG). We found that all maturation
stimuli induced significant increases in the expression of
costimulatory molecules (CD40, CD80, CD83 and CD86) while
only CD40 ligation evoked robust secretion of IL-12 (Figure 5).
DISCUSSION
In the present study we have characterised the systemic effects of
breast cancer on circulating DC in patients with early- and late-
stage disease and identified factors that improve their function for
immunotherapy. We found that blood DC numbers are only
modestly reduced in early disease but are significantly reduced in
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stage IV, n¼9), the level of expression of (A) CD86 and (B) HLA-DR was analysed according to the stage of disease and compared with controls (n¼14).
Shaded areas indicate normal reference ranges and box plots show means, standard deviations and ranges. (C and D) Antigen uptake of soluble (FITC-TT)
and particulate (FITC-Dextran) antigens by blood DC from patients with early (stage II, n¼7) and advanced (stage IV, n¼4) disease compared to controls
(n¼7) is presented as the difference in mean fluorescence intensity. (E) Allo-stimulatory capacity of blood DC as tested by mixed leucocyte reaction (MLR).
One representative experiment in which increasing numbers of blood DC purified from patients with early (stage II, n¼2) or advanced (n¼2) disease and a
healthy control (n¼1) were tested against allogeneic T cells purified from a panel (n¼3) of healthy volunteers. The pairs giving maximal responses are
shown as means of triplicate measurements. (F) Summary of proliferation data from MLRs using DC from patients with early (stage II, n¼6) and advanced
(stage IV, n¼3) disease compared to controls (n¼13) at a 1:30 DC:T ratio. Similar results were found for all DC:T ratios. (G) Summary of IFN-g secretion
in culture supernatants collected from MLRs at a 1:30 DC:T ratio as assessed by ELISA. Error bars correspond to s.e.m. Significant differences compared to
controls are shown as *Po0.05, **Po0.01 and ***Po0.001. All samples were analysed prior to therapy.
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spatients with more advanced disease. Importantly, DC counts are
consistently reduced in all patients with advanced disease
irrespective of their status (previously or newly diagnosed). The
marked decline in DC counts correlating with disease progression
indicates an incremental effect of the tumour on blood DC
populations. Previous evidence from in vitro studies has indicated
that tumour-derived factors can affect DC differentiation from
their progenitors, thus potentially reducing their numbers in
peripheral blood (Gabrilovich et al, 1996). In fact, reduced blood
DC counts have been reported in multiple myeloma (Ratta
et al, 2002), head and neck squamous cell carcinoma (Almand
et al, 2000; Hoffmann et al, 2002) and metastatic disease in
colorectal, gastric, lung and renal cell carcinoma (Lissoni et al,
1999). In breast cancer, blood DC counts have been found
decreased (Della Bella et al, 2003) although extensive comparative
analyses of early vs advanced disease have not yet been described.
Our results extend published data (Gabrilovich et al, 1997; Della
Bella et al, 2003; Satthaporn et al, 2004) and demonstrate that
diminished numbers of DC correlate with more extended disease.
Although patients with early disease showed only discrete (not
significant) reductions in counts at diagnosis, suppression of DC
was clearly evident upon follow-up. By monitoring DC counts over
48 weeks in patients with early disease, we found significant DC
suppression as early as 6 weeks post-surgery extending for over
1 year with no recovery. This is notable, because apart from
lymphocytes, all other blood counts (i.e. monocytes, neutrophils
and platelets) showed little alteration throughout the follow-up.
This is particularly relevant, given that monocytes are in vitro
precursors of DC (Sallusto and Lanzavecchia, 1994) thought to
differentiate into DC under inflammatory conditions in vivo
(Randolph et al, 1999). Our data, however, indicate that blood DC
and monocyte numbers are regulated differently and suggest that
in cancer patients, monocyte numbers may be maintained to
supply peripheral tissues, while blood DC could be specifically
suppressed, as described elsewhere (Pinzon-Charry et al, 2005c).
From an immunotherapy perspective, the finding that monocyte
numbers are not affected in patients with early- and/or late-stage
cancer is also relevant, because these cells are the most commonly
used precursor to generate DC for therapeutic applications.
The decline in blood DC counts in patients with early disease
maintained long after surgery contrasts with our previous study of
healthy individuals undergoing a surgical procedure. In those
patients, blood DC counts returned to pre-operative levels by day 7
(Ho et al, 2001), suggesting that in the current study, factors
different to surgical stress were playing a predominant role.
Adjuvant therapy (hormone, chemo- or radiotherapy) could be a
contributing factor. Despite the different therapeutic modality, we
found that patients receiving an aggressive course of systemic
chemotherapy (alone or in combination with radiotherapy) had a
similar decline in DC counts to patients receiving a more conser-
vative radiotherapy regimen. Interestingly, the drop in DC numbers
in all three groups (chemo-, radio- or combined therapy) coincided
with a reduction in lymphocytes, but not other cell populations.
This finding suggests a specific restraint on key elements of the
immune response, rather than the generalised suppression of
haematopoiesis expected as a consequence of antineoplastic
therapy. Although a definitive conclusion is difficult to reach due
to the limited number of patients available for analysis, the
suggestion that adjuvant (chemo/radio) therapy appears not to
exert a significant effect on numerical reconstitution of DC in
patients with early breast cancer is in accordance with a previous
report in a variety of cancers (Markowicz et al,2 0 0 2 ) .
Despite our endeavour, a controlled assessment of the effect of
hormone therapy on the abnormal DC count recovery in patients
with early disease was impossible due to the absence of control
cases (i.e., patients with early-stage breast cancer not receiving
hormone therapy). Only three patients not receiving hormone
therapy (yet administered radiotherapy) were assessed. These
patients demonstrated only moderate (not significant) reduction in
DC and lymphocyte counts compared to pre-operative assessment
possibly due to the small data set. It is plausible, however, that
ongoing adjuvant anti-oestrogen therapy may have had an effect
on the prolonged decrease in peripheral DC in these patients. In
fact, it has been shown that anti-estrogens (such as Tamoxifen)
inhibit the in vitro functional differentiation of human monocytes
(Komi and Lassila, 2000), synovial macrophages (Komi et al, 2001)
and murine splenic monocytes (Nalbandian et al, 2005) into DC,
and affect basic immunological functions such as cytokine and
chemokine expression (Bengtsson et al, 2004). However, there is
no evidence as yet to suggest blood DC levels are affected by
oestrogen inhibitors in vivo. Our results demonstrate that neither
DC nor lymphocyte counts are significantly different between
patients on hormone plus radiotherapy or those on radiotherapy
alone. In fact, counts appear remarkably similar. A recent
investigation into the function of plasmacytoid DC in female
subjects showed these cells to produce more IFN-a than their male
counterparts, a function not modified by oestrogen receptor
antagonism (Berghofer et al, 2006). These findings are in
agreement with our in vitro evaluation of blood DC in the
presence of various equivalent therapeutic doses of Tamoxifen,
showing no significant effect on DC phenotype or viability
(Pinzon-Charry, et al unpublished observations), indicating that,
at least, these features are independent of oestrogen modulation. In
future, a definitive conclusion will come from the assessment of
DC counts in healthy female subjects at risk of developing breast
cancer and for whom Tamoxifen is recommended, thus avoiding
the compounding effects of therapy and malignancy.
In our patients, it is also plausible that occult malignancy could
have contributed to the abnormal DC count recovery in the
longitudinal study (i.e. via tumour-derived factors or bone marrow
suppression). The high rate of spontaneous apoptosis in blood DC
from patients with early-stage breast cancer (Pinzon-Charry et al,
2005c), and the fact that early dissemination of tumour cells in
bone marrow has been found in 20–40% of patients assigned to
early-stage disease (Janni et al, 2000) support this assumption.
Interestingly, we found DC were suppressed in a coordinated
fashion with lymphocyte but not other blood counts. At face value,
this might be interpreted as specific suppression of two key
interacting components of a cognate immune response, a well-
described mechanism of tumour-induced suppression (Pinzon-
Charry et al, 2005b). In breast cancer, it has been demonstrated
that lymphopenia can be completely independent of treatment
modalities known to affect immune function (radio/chemo-
therapy) and instead appears to be a clear indicator of the host’s
response to tumour growth (Papatestas and Kark, 1974). While our
results confirm these data, the 48-week follow-up period does not
allow us to determine an association between reduced DC counts,
as an index of immune competence, and tumour relapse.
Prolonged follow-up of these patients (i.e. until tumour recur-
rence) would be necessary.
The assumption that tumour progression is associated with
increasing immune cell suppression is further supported herein by
the marked decrease in DC counts observed in patients with higher
tumour burdens (metastatic disease). While it may be suggested that
decreased DC numbers could reflect increased migration into the
tumour site, previous reports indicate the contrary (Bell et al,1 9 9 9 ;
Coventry et al, 2002). A more plausible explanation would relate to
tumour-induced suppression of DC populations while in circulation.
In fact, significant apoptosis of blood DC in patients with breast
cancer has been reported to be associated with tumour products
(Pinzon-Charry et al, 2005c). This phenomenon would certainly
impose chronic stress on the immune system of these patients and
result in progressive paucity of DC in the circulation (Lissoni et al,
1999; Della Bella et al, 2003), failure to replenish tumour-infiltrating
DC and impaired migration of DC to lymphoid organs (Satthaporn
et al, 2004) for the initiation of T-cell responses.
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DC from patients with early disease support the notion that DC
impairment is present even in the absence of overt numerical or
phenotypic alterations. The important implication for these
patients is that although DC may ‘seem’ normal, their reduced
functionality (Gabrilovich et al, 1997; Della Bella et al, 2003;
Satthaporn et al, 2004) could indeed favour tumour progression by
failing to induce adequate antitumour immunity. From an
immunotherapy standpoint, such in vivo deficiencies should be
overcome (Pinzon-Charry et al, 2006a). Here, by testing a range of
clinically available maturation factors, we identified an appropriate
stimulus to condition blood DC from breast cancer patients with
early- and late-stage disease. Our results show that although
responses in patients do not reach control values, CD40
stimulation induces a vigorous maturation and secretion of IL-12,
thus generating better T-cell responses than those induced by all
other factors tested. As a key molecule in the interface between T
cells and DC, CD40L has long been recognised as an important
element to license APC for efficient antitumour T-cell priming
(Terheyden et al, 2000; Onaitis et al, 2003). However, limited
reports on the clinical use of CD40L-conditioned DC for cancer
immunotherapy are available (Davis et al, 2006). While our
findings advance this reagent as one of the most potent stimuli for
improving blood DC and further support its use to condition DC
for breast cancer immunotherapy (Pinzon-Charry et al, 2006a,b),
its application in a clinical setting remains to be established.
In summary, this study demonstrates that the blood DC
compartment is compromised in patients with early as well as
late breast cancer, suggesting a correlation between DC impair-
ment and tumour burden. While our data identify CD40L as one of
the most potent stimulus to condition blood DC from patients with
breast cancer, studies on the combined use of TLR ligands with
pro-inflammatory cytokines demonstrate that combinatorial
stimulation provide strong IL-12 secretion in vitro and thus may
provide a better biological framework on which to develop
effective DC-based immunotherapies for breast cancer.
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